Athiyyah, Alpha Fardah and Nindya, Triska Susila and Ranuh, Reza Gunadi and Darma, Andy and Sumitro, Khadijah Rizky and Rejeki, Purwo Sri and Djuari, Lilik and Sudarmo, Subijanto Marto and Agustina, Rina (2025) Role of oral probiotic supplementation on gut permeability in obesity: A systematic review of randomized controlled trials. Food Hydrocolloids for Health, 8.
![[img]](https://repository.unair.ac.id/style/images/fileicons/text.png) |
Text (Article)
1-s2.0-S2667025925000317-main.pdf Download (1MB) |
Abstract
Background: Obesity is a chronic condition and a global epidemic, associated with impaired intestinal permeability owing to dysbiosis. Gut microbiota reportedly plays a potential role in obesity treatment. Probiotics have emerged as the most widely used approach for treating dysbiosis. This study explored the effect of oral probiotic supplementation on intestinal permeability in individuals with obesity. Methods: A Systematic review was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses. PubMed, ScienceDirect, PLOS One, and Cochrane databases were searched to identify articles published between 2014 and September 2024. The Cochrane risk-of-bias tool for randomized trials was used to assess publication bias. Results: A total of 690 human RCTs (randomized controlled trials) were identified, of which nine were eligible for this review. Probiotics (Akkermansia, Bifidobacterium, Enterococcus, Lactobacillus, Streptococcus, and a combination of Saccharomyces yeast) used for over 8 weeks may decrease gut permeability outcomes, including plasma zonulin, fecal zonulin, plasma or serum LPS, urinary lactulose, and urinary mannitol; however, BMI (body mass index) levels exhibited inconsistent measurements across all groups. Conclusions: Probiotic supplementation for a minimum of 8 weeks may reduce gut permeability. However, further studies are required to develop standardized protocols for probiotic strains, dosages, durations, and delivery methods, to better understand their effects on intestinal permeability and related outcomes in individuals with obesity. © 2025
| Item Type: | Article | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Additional Information: | Cited by: 0; All Open Access; Gold Open Access; Green Open Access | ||||||||||||||||||||
| Uncontrolled Keywords: | lactulose; mannitol; probiotic agent; protein zonulin; unclassified drug; Akkermansia; Article; Bifidobacterium; blood sampling; body mass; drug dose regimen; drug effect; drug urine level; Enterococcus; evidence based practice; human; information processing; intestine mucosa permeability; Lactobacillus; nonhuman; obesity; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; protein blood level; quality control; randomized controlled trial (topic); risk assessment; Saccharomyces; Streptococcus; systematic review; treatment duration; treatment outcome | ||||||||||||||||||||
| Subjects: | R Medicine | ||||||||||||||||||||
| Divisions: | Artikel Ilmiah > SCOPUS INDEXED JOURNAL | ||||||||||||||||||||
| Creators: |
|
||||||||||||||||||||
| Depositing User: | Nurma Harumiaty | ||||||||||||||||||||
| Date Deposited: | 02 Oct 2026 09:14 | ||||||||||||||||||||
| Last Modified: | 02 Oct 2026 09:14 | ||||||||||||||||||||
| URI: | http://repository.unair.ac.id/id/eprint/145928 | ||||||||||||||||||||
| Sosial Share: | |||||||||||||||||||||
Actions (login required)
 |
View Item |